Endosonographic diagnosis of advanced neoplasia in intraductal papillary mucinous neoplasms

Andrew Eiterman, Ali Lahooti, Somashekar G Krishna

ORCID number: Andrew Eiterman (0000-0002-8505-9516); Ali Lahooti (0000-0003-3708-2102); Somashekar G Krishna (0000-0001-5748-7890).

Author contributions: Eiterman A and Krishna SG provided literature review, designed the structure of this manuscript, drafted the manuscript, and contributed critical revisions to this manuscript; Lahooti A performed drafting of manuscript.

Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed efforts in this manuscript.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Received: February 27, 2020
Peer-review started: February 27, 2020
First decision: April 12, 2020
Revised: April 25, 2020
Accepted: June 5, 2020

Abstract
Pancreatic cancer has a high mortality rate with minimal proven interventions. Intraductal Papillary Mucinous Neoplasms (IPMNs) are known precursor lesions for pancreatic cancer. Identification of pancreatic cysts has improved from advances in abdominal imaging. Despite multiple revisions of the international consensus recommendations and various guidelines by other major societies, successful risk stratification of the malignant potential of mucinous pancreatic cysts remains challenging. Specifically, detection and accurate classification of advanced neoplasia (high-grade dysplasia and/or adenocarcinoma) in IPMNs is suboptimal with current diagnostic strategies. Development of interventional techniques utilizing endoscopic ultrasound include - through-the-needle microforceps biopsy, next-generation or whole genome molecular analysis of cyst fluid, and needle-based confocal laser endomicroscopy. These techniques suffer from a series of limitations in technical success, diagnostic yield, and clinical feasibility, but a combination approach may offer a solution that optimizes their cyst evaluation and risk stratification. Assessment and comparison of these techniques is restricted by lack of adequate surgical specimens for testing of diagnostic accuracy, resulting in a possible sample bias. Additional large-scale multicenter studies are needed to accumulate evidence for the utility and feasibility of their translation into clinical practice. Great strides have been made in pancreatic cyst evaluation, but further research is required to improve diagnostic accuracy and clinical management of IPMNs.

Key words: Pancreatic cyst; Confocal endomicroscopy; Microforceps biopsy; Cyst fluid molecular analysis; Endoscopic ultrasound; Intraductal papillary mucinous neoplasms

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
INTRODUCTION

Advances in abdominal imaging techniques have led to an increase in detection and diagnosis of pancreatic cystic lesions (PCLs)\(^1,2\). Although the majority of pancreatic cysts are asymptomatic and do not progress to adenocarcinoma, the ability to differentiate precancerous versus benign lesions and further estimate the risk for malignant transformation of precancerous lesions remains a challenge in the field\(^3,4\). Among all solitary PCLs, branch duct (BD) intraductal papillary mucinous neoplasms (IPMN) are the most common type of precancerous lesions, and are often referred for surveillance due to their low chance of progressing to cancer\(^5\). However, even with the use of international consensus guidelines (ICG) for the evaluation of mucinous PCLs, advanced neoplasia (high grade dysplasia or adenocarcinoma) is frequently missed\(^5\). Moreover, surgery for PCLs must be highly selective since the risk of long-term significant morbidity is 30% with a 2.1% mortality rate\(^6\). Thus, a sensitive and accurate method measuring risk for advanced neoplasia in BD-IPMNs is critical to determine an optimal timeline for intervention for lesions that can potentially progress to adenocarcinoma.

Reflecting on morbidity rates for cyst resection, the recommendation of resection is becoming more heavily scrutinized. Determining the presence of low-grade or high-grade dysplasia informs the need and urgency for intervention, but evaluating dysplasia with current assessment methods remains a challenge\(^1\). A study by Sahora et al\(^7\) found that an estimated 75% of resected IPMNs were evaluated as low grade dysplasia that could have instead been monitored\(^7\). Additional studies have reported that for patients identified as having high-grade dysplasia, early identification significantly improved survival rates and eliminated or reduced risk for recurrence\(^8,9\). Thus, advances in identifying the risk and rate of transformation to advanced neoplasia could inform the ideal point for surgical intervention\(^10\).

Risk assessment techniques in the field are lacking methods that can be used with frequency, possess excellent sensitivity and specificity, and are minimally invasive. First line assessment includes imaging techniques, followed by more invasive imaging or biopsy methods via endoscopic ultrasound (EUS)\(^1\). Computed tomography and magnetic resonance imaging technology provide abdominal imaging to characterize the cyst type and preemptively assess for the presence of high-risk or concerning features\(^1,11\). Cyst morphology on EUS imaging has similar accuracy in diagnosing a benign from malignant cyst to that of magnetic resonance imaging but is more invasive\(^1\). Additional methods that use EUS-guided technology can include fine needle aspiration (FNA), through-the-needle microforceps biopsy (EUS-MFB), and needle-based confocal laser endomicroscopy (EUS-nCLE). Advances in these techniques aim to address the critical need to assess risk for malignant transformation in IPMNs. These techniques and their feasibility for clinical adaptation will be summarized in this review.

HOW DO THE GUIDELINES PERFORM?

Clinical guidelines assist in the identification of advanced neoplasia in PCLs. The major society guidelines include 2012 and 2017 revised ICG, 2015 American Gastroenterological Association (AGA) guidelines, and the 2018 American College of Gastroenterology guidelines\(^11,12\). Changes in guidelines have improved identification of advanced neoplasia in IPMNs. Sighinolfi et al\(^13\) retrospectively validated the 2006
ICG, 2012 ICG, and AGA criteria, where the 2012 ICG and AGA showed significantly improved specificity (58.2% and 62.4%, respectively) and diagnostic accuracy (67% and 68%, respectively) for advanced neoplasia compared to the 2006 ICG (specificity 32.7%, diagnostic accuracy 46%)[13]. Additionally, Kang et al[14] have demonstrated superior diagnostic performance of the 2017 ICG [area under the curve (AUC) 0.78] compared to 2012 ICG criteria (AUC 0.74) for the detection of malignancy in BD-or mixed-type IPMNs[14]. Yet, these consensus opinions remain suboptimal, and there is need for improved cyst surveillance methods and timing of surgical intervention.

ENDOCOSOPIC ULTRASOUND-GUIDED METHODOLOGY FOR RISK STRATIFICATION OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS

Molecular analyses of cyst fluid
Cystic fluid carcinoembryonic antigen (CEA) acquired from EUS-FNA reflects a pooled 66% specificity and 65% sensitivity in identifying mucinous PCLs, yet it is not helpful in differentiating low- vs high-grade dysplasia[15,18]. Overall, EUS-FNA has moderate diagnostic strength in identifying benign and malignant lesions, but lacks ability to monitor risk and progression of advanced neoplasia in the absence of obvious EUS-imaging morphological features of malignancy[17]. However, building on the use of this technique, as well as addressing its limitations, recent research has advanced to integrate the use of molecular and genetic testing from acquired cyst fluid as a potential solution for risk assessment[18].

Using analysis of DNA or miRNA mutations via algorithms developed with whole-genome sequencing techniques, distinct genetic profiles have been developed to identify risk for malignant transformation from cystic fluid (Table 1)[19,21]. Mutations in KRAS and GNAS have been specifically targeted, with 100% sensitivity and 96% specificity for the detection of IPMN. In addition, these mutations resulted in an 89% sensitivity and 100% specificity for IPMN and mucinous cystic neoplasms combined[21].

Combination KRAS/GNAS with additional mutations in TP53, PIK3CA, and PTEN showed 88% sensitivity, 97% specificity for IPMN with advanced neoplasia[14]. Additional mutations in TP53, PIK3CA, and PTEN testing showed 79% sensitivity, 96% specificity for all mucinous pancreatic cysts with advanced neoplasia, showing potential for the role of molecular analyses in risk stratification of cysts. Other genes that have proven useful in risk stratification of IPMNs include SMAD4, RNF43, and CDKN2A[19-21].

The benefits of such a technique address some of the previous sampling limitations of EUS-FNA CEA analysis, as molecular analysis uses a very small amount of cyst fluid (0.25 mL fluid) and can be helpful when aspirated volume is an issue[22]. However, challenges with this technique include - reproducibility (replicating single center results in multicenter prospective studies), and feasibility for general hospitals[22]. Further, studies to date exploring the molecular markers have often used post-resected biologic specimens, thus creating the possibility for bias in the pathology of samples. Additional studies are needed to identify an adequate panel of genes for assessment of pancreatic cysts[19]. Results were also cross-validated using standard techniques such as cytology/CEA, whose sampling errors often results in discordant pairs of specimens for correlation, given challenges in diagnostic yield[23]. Major advancements in this method have yet to solve the problem of monitoring risk for progression to advanced neoplasia, but its feasibility for repeated usage in clinical surveillance is optimistic[24].

EUS-guided microforceps biopsy
A relatively novel procedure, EUS-MFB utilizes through-the needle microforceps to acquire a tissue biopsy from PCLs for histologic analysis (Table 2)[25]. There is paucity of large, randomized trials evaluating EUS-MFB in PCLs; however, multiple systematic reviews and meta-analyses have sought to further evaluate the utility of this device. Most of these studies (Table 2) address only diagnostic yield without the estimation of diagnostic accuracy. Tacelli et al[25] reviewed 9 studies evaluating EUS-MFB; technical success was achieved in 98.5% [95% confidence interval (CI): 97.3%-99.6%, P (measure of heterogeneity) = 88.6%], specimen adequacy was achieved in 86.7% (95% CI: 80.1%-93.4%, F = 84.3%), the pooled diagnostic yield was 69.5% (95% CI: 59.2%-79.7%, F = 84.7%; P < 0.001), and pooled rate of adverse events was 8.6%[23]. Another recent meta-analyses by Facciorusso et al[26], involving 11 studies, revealed that specimen adequacy was 85.3% (95% CI: 78.2%-92.5%, P = 41.5%), pooled diagnostic accuracy (8 of 11 studies) was 78.8% (95% CI: 73.4%-84.2%, P = 28.4%), and
| Ref.                | Design                                             | Sample                                                                 | Specific cyst type (NGS/surgery) | Sensitivity/ specificity | Key findings |
|-------------------|---------------------------------------------------|------------------------------------------------------------------------|----------------------------------|-------------------------|--------------|
| Springer et al[22], 2015 | Retrospective, multi-center, whole genome sequencing algorithm | n = 130 patients with surgical pathology                             | NA/12 NA/22 NA/62 - NA/12       |                         | NGS identified IPMNs with 76% sensitivity and 97% specificity from presence of mutation in GNAS, RNF43, LOH in chromosome 9, or aneuploidy in chromosome 1q or 8p. Use of this molecular algorithm can avoid unnecessary surgery and is relatively sensitive for high risk cysts. Adding clinical markers and radiologic features improved sensitivity to 94% but decreased specificity to 84%. |
| Singhi et al[16], 2016 | Retrospective, molecular testing of cyst fluid with novel algorithmic pathway | n = 225 patients; n = 41 patients with surgical pathology              | 9/9 1/2 12/12 - 1/2            |                         | Six cancer genes targeted KRAS/GNAS sensitivity 100%, specificity 100% for IPMN, TP53, PIK3CA, and/or PTEN sensitivity 91%, specificity 97% for IPMN with advanced neoplasia. Integrating molecular testing with clinical features and cytopathology into algorithm resulted in sensitivity and specificity for advanced neoplasm of 100% and 90%, respectively. |
| Jones et al[49], 2016 | Prospective, NGS                                   | n = 79 patients (92 PCL samples), n = 14 with surgical pathology      | 1/4 0/2 4/4 - -                |                         | Thirty-nine cancer genes targeted, specificity and sensitivity for NGS was 75% and 86%, specificity and sensitivity for CEA was 100% and 57%, NGS was more sensitive but CEA was more specific for identifying mucinous etiology. A KRAS mutation reclassified 19% of cysts as mucinous that were originally identified as nonneoplastic and nonmucinous from CEA, 20% of cysts identified as nonmucinous by imaging were identified as mucinous by NGS. A KRAS/GNAS mutation correlated with nonmucinous CEA in 71% of IPMNs. |
Rosenbaum et al.\[50\], 2016

| NGS | Retrospective | n = 113 PCL samples (105 patients); n = 25 patients with surgical pathology | NA | NA | NA | NA | Nine cancer genes targeted, Detection of a KRAS variant yielded 80% sensitivity and 88% specificity for IPMN or carcinoma, GNAS variant yielded 27% sensitivity and 100% specificity for IPMN or carcinoma. Combining cytology, CEA, and NGS yielded a 90% sensitivity and 88% specificity for IPMN or carcinoma |

Singhi et al.\[18\], 2018

| FNA of cyst fluid with NGS | Prospective | n = 626 PCL samples from 595 patients; n = 102 patients with surgical pathology | 13/13 | 4/4 | 39/39 | 0/2 | 2/8 | Eleven cancer genes targeted, KRAS/GNAS sensitivity 100%, specificity 96% for detection of IPMN; and 89% sensitive and 100% specific for IPMN and MCNs combined, Combination KRAS/GNAS with TP53, PIK3CA, and PTEN testing showed 88% sensitivity, 97% specificity for IPMN with advanced neoplasia, Combination KRAS/GNAS with TP53, PIK3CA, and PTEN testing showed 79% sensitive, 96% specific for all mucinous pancreatic cysts with advanced neoplasia |

1No reported mutant allele frequencies which may impact risk stratification for 2 high-grade dysplasia intraductal papillary mucinous neoplasm.
2Identified by alterations in TP53, PIK3CA and/or PTEN; not KRAS or GNAS. IPMN: Intraductal papillary mucinous neoplasm; IPMN-Ca: IPMN with adenocarcinoma; HGD: High-grade dysplasia; LGD: Low-grade dysplasia; NGS: Next-generation sequencing; CEA: Carcinoembryonic antigen; NA: Not available.

The risk of adverse events was 8.98%.\[26\]. In a study by Larghi et al.\[27\], where EUS-MFB specimens (n = 40) were retrieved and evaluated by pathologists (n = 6), the interobserver agreement among pathologists was almost perfect for specimen adequacy (Gwet’s AC1 0.82, 95%CI: 0.79-0.98), and substantial for the diagnosis of PCL (AC1 0.62, 95%CI: 0.57-0.67).\[27\]

EUS-MFB likely solves the problems of low cellular cystic fluid acquisition by instead sampling tissue from the epithelium lining the cyst wall, as well as tissue beyond the epithelium.\[25,28\] It has been demonstrated that obtaining two macroscopically visible tissue samples reached optimal histologic adequacy and specifically, identification of stroma beyond the epithelium greatly assists in diagnosis.
| Ref.          | Design                      | Sample                                                                 | Specific cyst type (MFB/surgery) | Results                                                                 | Additional key findings                                                                 |
|--------------|-----------------------------|------------------------------------------------------------------------|---------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------------------------|
| Basar et al[51], 2018 | Retrospective, open label, multicenter; MFB | n = 42 patients; n = 7 surgical pathology                              | 2/2                             | 0/0                                                                    | 1/1                                                                                      |                                                                                           |
| Kovacevic et al[31], 2018 | Retrospective, MFB          | n = 31 patients; n = 18 FNA cytology; n = 4 surgical pathology        | 0/1                             | 0/0                                                                    | 3/2                                                                                      |                                                                                           |
| Mittal et al[52], 2018   | Retrospective, EUS-MFB      | n = 27 patients                                                        | 0/0                             | 0/0                                                                    | 1/3 NA                                                                                   |                                                                                           |
| Yang et al[53], 2018     | Retrospective, EUS-MFB      | n = 47 patients; n = 8 surgical pathology                              | 0/0                             | 2/2                                                                    | 4/5 NA                                                                                   |                                                                                           |
| Zhang et al[54], 2018    | Retrospective, MFB          | n = 48 patients                                                        | 1/3                             | 1/0                                                                    | 4/4                                                                                      |                                                                                           |
Crinò et al.[5], 2019  
Retrospective, EUS-MFB  
$n = 61$ patients  
- - -  
0/1  
11/12  
Diagnostic reliability of EUS-MFB compared to surgery was 90% vs 20% CFC  
Two EUS-MFB histologic samples resulted in a specific cyst diagnosis in 74% of cases; 100% histological adequacy reached with two EUS-MFB samples  

Yang et al.[24], 2019  
Prospective, Open Label, EUS-MFB  
$n = 114$ patients; $n = 23$ surgical pathology  
2/2  
2/2  
5/5  
3/3  
1/1  
Specificity for EUS-MFB was 100% vs 21.4% CFC; EUS-MFB was diagnostic to the degree of dysplasia by 80% vs 0% CFC  
Tissue acquisition reached 83.3% with EUS-MFB vs 37.7% with FNA; Findings from EUS-MFB were 100% concordant with analysis from resection vs 21.4% with CFC alone  

1False negative by micro-forceps biopsy, surgery identified as adenocarcinoma.  
2Cysts classified as mucinous, but not differentiated into intraductal papillary mucinous neoplasm or mucinous neoplasm.  
3Intraductal papillary mucinous neoplasms with no dysplasia subtype were grouped as intraductal papillary mucinous neoplasm low-grade dysplasia.  
4Undiagnostic on micro-forceps biopsy. IPMNs: Intraductal papillary mucinous neoplasms; IPMN-Ca: IPMN with adenocarcinoma; HGD: High-grade dysplasia; LGD: Low-grade dysplasia; MFB: Micro-forceps biopsy; CFC: Cystic fluid cytology; FNA: Fine needle aspiration; MCN: Mucinous neoplasm; NA: Not available.  

Studies utilizing EUS-MFB have addressed the diagnostic yield, feasibility, technical success, and associated adverse events. However, there are no comparative large prospective studies with assessment of diagnostic accuracies where the reference standard is surgical histopathology and the lack of this diminishes the full impact of this novel diagnostic modality in the management of PCLs.

**EUS guided needle confocal laser endomicroscopy**  
EUS guided needle confocal laser endomicroscopy is a novel *in vivo* imaging technique that grants real-time, high-resolution microscopic imaging of the pancreatic cyst epithelium. Major trials (INSPECT, DETECT, CONTACT, and INDEX) have established feasibility, diagnostic image standard, and characteristic CLE patterns of pancreatic cysts routinely evaluated in clinical practice[32-37]. In the INDEX study, investigators confirmed the *in vivo* nCLE features on *ex vivo* post-resection specimens of IPMNs[38,39], and also validated EUS-nCLE image patterns of mucinous PCLs including IPMNs among blinded external CLE-expert observers[40]. In a post-hoc analysis of the INDEX study, quantification of the papillary epithelial width and darkness (pixel intensity) was able to predict advanced neoplasia in IPMNs (Figure 1). The study included 26 IPMNs (high-grade dysplasia-Ca in 16) with histopathological ($n = 24$) or cytological ($n = 2$) reference standard. For diagnosing advanced neoplasia, CLE features of increased papillary epithelial “width” with cut-off value of ≥ 50 μm revealed a sensitivity, specificity, and AUC of 87.5%, 100%, and 0.95, respectively.
Similar diagnostic values of sensitivity, specificity, and AUC of 87.5%, 100%, and 0.95, respectively, were observed for papillary darkness (pixel-intensity) cut-off value ≤ 90 pixels (lower values being darker). The pathology of IPMNs presents a papillary configuration that includes a spectrum of dysplastic mucinous epithelium ranging from low-to-high grade dysplasia\cite{41,42}. While low-grade dysplasia demonstrates a single flat layer of columnar cells with retained polarity, high-grade dysplasia demonstrates loss of nuclear polarity, increased nuclear-cytoplasmic ratio, stratification of both the columnar cells and their nuclei, and complex architecture\cite{42}. In parallel to these pathological changes, IPMNs with low-grade dysplasia reveal a thin layer of epithelium (Figure 1), whereas advanced neoplasia reveals thicker and darker epithelium since CLE imaging of the nuclei reveals dark spots, which when stratified imparts a darker hue to the epithelium. Thus, the consequence of a combination of cellular and nuclear stratification is thicker and darker epithelium of the papillae (Figure 1). Qualitative image interpretation by an endoscopist is susceptible to interobserver disagreement and quantitative estimation of papillary thickness and darkness can be laborious. Hence, computer-aided quantification utilizing machine learning and artificial intelligence would need to be adapted to reduce interobserver disagreement and endoscopist work load.

Similar to other EUS-guided evaluations, nCLE differentiation of dysplasia in IPMN needs to be reproducible and validated in prospective multi-center studies. If endomicroscopy assisted machine learning and artificial algorithms are generated, these would need to be validated in multicenter studies across multiple centers and endoscopists. Since the entire cyst is not imaged during CLE, theoretically the modality cannot be utilized to rule-out advanced neoplasia in IPMNs. Despite the limitations in the maneuverability of the EUS-FNA needle (19-g), approximately 30%-50% of the PCLs can be observed depending on the location of the neoplasm in the pancreas.

CONCLUSION

Pancreatic adenocarcinoma is a near fatal diagnosis with a < 10% 5-year overall survival rate, and there are no pragmatic investigations for screening with proven efficacy\cite{43}. Analogous to other adenocarcinomas such as esophageal and colorectal cancer, the resection of a premalignant lesion such as IPMN should prevent development of pancreatic adenocarcinoma; however, the operative morbidity of pancreatic surgery is high, the natural history of BD-IPMNs (< 3 cm) has not been delineated, and it is challenging to diagnose BD-IPMNs with advanced neoplasia\cite{41}. Despite multiple revisions of the international consensus guidelines and various guidelines by other major societies\cite{11,12,44,45}, there continues to be range of percentage of patients (up to 2/3\textsuperscript{rd} of resections at tertiary care centers) who have low-grade dysplasia on postoperative pathology\cite{46-48}.

Improved diagnostics are needed that are sensitive and accurate in identifying dysplasia, as well as informing an appropriate timeline for intervention when considering risk of malignant transformation. Each of the methods explored in this manuscript, through-the-needle tissue biopsy/MFB, molecular analysis, and nCLE, have attempted to address this need. Collectively these methods suffer from potential sample bias given the limited amount of surgical specimen pathology available to confirm diagnostic accuracy. There is inherent need for improved sample size to refine these methods, which will likely only be attained from large-scale multisite studies. These methods each have individual limitations, and it may be prudent to evaluate a combination of techniques to optimize clinical feasibility and diagnostic accuracy. In summary, great strides have been made in the evaluation of pancreatic cysts, but there is still a critical need for further research to classify the risk for malignant potential.
Figure 1  Endoscopic ultrasound-guided confocal endomicroscopy characteristics of intraductal papillary mucinous neoplasm. A-C: Intraductal papillary mucinous neoplasm with low-grade dysplasia. Papillae (blue arrows) reveal thin and translucent epithelium. The papillae are small with thin epithelium in panel A. The epithelium is flat in panels B and C. D-H: Intraductal papillary mucinous neoplasm with high-grade dysplasia. Papillae (orange arrows) show thicker and darker epithelium. In panel D, there is higher density of papillae.

REFERENCES

1. Elta GH, Enestvedt BK, Sauer BG, Lennon AM. ACG Clinical Guideline: Diagnosis and Management of Pancreatic Cysts. Am J Gastroenterol 2018; 113: 464-479 [PMID: 29485131 DOI: 10.1038/ajg.2018.14]

2. Klansky DA, Reid-Lombardo KM, Gordon SR, Gardner TB. The clinical relevance of the increasing incidence of intraductal papillary mucinous neoplasm. Clin Gastroenterol Hepatol 2012; 10: 555-558 [PMID: 22210438 DOI: 10.1016/j.cgh.2011.12.029]

3. Gardner TB, Glass LM, Smith KD, Ripple GH, Barth RJ, Klansky DA, Colacchio TA, Tsapakos MJ, Suriawinata AA, Tsongalis GJ, Pipas JM, Gordon SR. Pancreatic cyst prevalence and the risk of mucin-producing adenocarcinoma in US adults. Am J Gastroenterol 2013; 108: 1546-1550 [PMID: 24091499 DOI: 10.1038/ajg.2013.103]

4. Stark A, Donahue TR, Reber HA, Hines OJ. Pancreatic Cyst Disease: A Review. JAMA 2016; 315: 1882-1893 [PMID: 2719061 DOI: 10.1001/jama.2016.4690]

5. Heckler M, Michalski CW, Schaeffe S, Kaiser J, Büchler MW, Hackert T. The Sendai and Fukuoka consensus criteria for the management of branch duct IPMN - A meta-analysis on their accuracy. Panreatology 2017; 17: 255-262 [PMID: 28189431 DOI: 10.1016/j.pan.2017.01.011]

6. Scheiman JM, Hwang JL, Moayyedi P. American gastroenterological association technical review on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology 2015; 148: 824-848.e22 [PMID: 25805376 DOI: 10.1053/j.gastro.2015.01.014]

7. Sahora K, Mino-Kenudson M, Brugge W, Thayer SP, Ferrone CR, Sahani D, Pitman MB, Warshaw AL, Lillemoe KD, Fernandez-del Castillo CF. Branch duct intraductal papillary mucinous neoplasms: does cyst size change the tip of the scale? A critical analysis of the revised international consensus guidelines in a large single-institutional series. Ann Surg 2013; 258: 466-475 [PMID: 24022439 DOI: 10.1097/SLA.0b013e3182af092f]

8. Griffin JF, Page AJ, Samaha GJ, Christopher A, Bhaijee F, Pezhouh MK, Peters NA, Hruban RH, He J, Makary MA, Lennon AM, Cameron JL, Wolfgang CL, Weiss MJ. Patients with a resected pancreatic mucinous cystic neoplasm have a better prognosis than patients with an intraductal papillary mucinous neoplasm: A large single institution series. Panreatology 2017; 17: 490-496 [PMID: 28416122 DOI: 10.1016/j.pan.2017.04.003]

9. Lennon AM, Wolfgang CL, Canto MI, Klein AP, Herman JM, Goggins M, Fishman EK, Kamei I, Weiss MJ, Diaz LA, Papadopoulos N, Kinzler KW, Vogelstein B, Hruban RH. The early detection of pancreatic cancer: what will it take to diagnose and treat curable pancreatic neoplasia? Cancer Res 2014; 74: 3381-3389 [PMID: 24924775 DOI: 10.1158/0008-5472.CAN-14-0734]

10. Rezaee N, Barbon C, Zaki A, He J, Hruban RH, Cameron JL, Herman JM, Ahuja N, Lennon AM, Weiss MJ, Wood LD, Wolfgang CL. Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma. HPB (Oxford) 2016; 18: 236-246 [PMID: 27017163 DOI: 10.1016/j.hpb.2015.10.010]

11. Tanaka M, Fernández-Del Castillo C, Kamisawa T, Jang JY, Levy P, Ohtsuka T, Salvia R, Shimizu Y, Tada M, Wolfgang CL. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Panreatology 2017; 7: 738-753 [PMID: 28755806 DOI: 10.1016/j.pan.2017.07.007]

12. Vege SS, Ziring B, Jain R, Moayyedi P; Clinical Guidelines Committee; American Gastroenterology Association. American gastroenterological association institute guideline on the diagnosis and
management of asymptomatic neoplastic pancreatic cysts. *Gastroenterology* 2015; 148: 819-22; quiz12-3

[PMID: 25805375 DOI: 10.1053/j.gastro.2015.01.015]

13 Sighinolfi M, Quan SY, Lee Y, Ibaseta A, Pham K, Daun MM, Poultsides GA, Visser BC, Norton JA, Park WG. Fukuoka and AGA Criteria Have Superior Diagnostic Accuracy for Advanced Cystic Neoplasms than Sendai Criteria. *Dig Dis Sci* 2017; 62: 626-632 [PMID: 28116593 DOI: 10.1007/s00410-017-4460-y]

14 Kang JS, Park T, Han Y, Lee S, Lim H, Kim H, Kim SH, Kwon W, Kim SW, Jang JY. Clinical validation of the 2017 international consensus guidelines on intraductal papillary mucinous neoplasm of the pancreas. *Ann Surg Treat Res* 2019; 97: 58-64 [PMID: 31385508 DOI: 10.4174/astc.2019.97.2.58]

15 Ngamrungphong S, Bartel MJ, Raimondolo M. Cyst carcinoembryonic antigen in differentiating pancreatic cysts: a meta-analysis. *Dig Liver Dis* 2013; 45: 920-926 [PMID: 23790460 DOI: 10.1016/j.dld.2013.05.002]

16 Singh AD, Zeh HJ, Brand RE, Nikiforova MN, Chennai JS, Fasanella KE, Khalid A, Papachristou GI, Slivka A, Bartlet DL, Dayam AK, Hogg M, Lee KK, Marsh JW, Monan SE, Oheri NP, Pingpaka J, Tsang A, Zureikah AI, Wald AI, Nikiforova MN. Preoperative next-generation sequencing of pancreatic cystic fluid is highly accurate in cyst classification and detection of advanced neoplasia. *Gut* 2018; 67: 2131-2141

[PMID: 28970292 DOI: 10.1136/gutjnl-2016-313586]

17 Wu J, Jiao Y, Dal Molin M, Mairia A, de Wilde RF, Wood LD, Estehman JR, Goggins MG, Wolfgang CL, Canto MJ, Schullik RD, Edil BH, Chot M, Asoy V, Klimistra DS, Offer JR, Klein AJ, Kopelowicz L, Carter H, Karchin R, Allen PJ, Schmidt CM, Naito Y, Diaz LA Jr, Knizler KW, Papadopoulos N, Bruban RH, Vogelstein B. Whole-exome sequencing of neoplastic cysts of the pancreas reveals reveals mutations in components of ubiquitin-dependent pathways. *Proc Natl Acad Sci USA* 2011; 108: 21188-21193 [PMID: 22159986 DOI: 10.1073/pnas.1110461108]

18 Wu J, Mathiath H, Mairia A, Dal Molin M, Wood LD, Estehman JR, Goggins M, Canto MJ, Schullik RD, Edil BH, Wolfgang CL, Klein AP, Diaz LA Jr, Allen PJ, Schmidt CM, Knizler KW, Papadopoulos N, Bruban RH, Vogelstein B. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. *Sci Transl Med* 2011; 3: 92ra66 [PMID: 21775669 DOI: 10.1126/scitranslmed.3002543]

19 Hao S, Takashia C, Snyder RA, Parkh A, Arashi A. Stratifying Intraductal Papillary Mucinous Neoplasms by Cyst Fluid Analysis: Present and Future. *Int J Mol Sci* 2020; 21 [PMID: 32054665 DOI: 10.3390/ijms21031417]

20 Springer S, Yang D, Dal Molin M, Kasaka DL, Jiao Y, Kinde I, Blackford A, Raman SP, Wolfgang CL, Tomita T, Nikfors N, Douville C, Pich J, Dobyns L, Allen PJ, Klimistra DS, Schattner MA, Schmidt CM, Yip-Schneider M, Cummings OW, Brand RE, Zeh HJ, Singh AD, Zureikah AI, Wald AI, Nikiforova MN. Preoperative next-generation sequencing of pancreatic cystic fluid is highly accurate in cyst classification and detection of advanced neoplasia. *Gastroenterology* 2015; 149: 1501-1510 [PMID: 26253305 DOI: 10.1053/j.gastro.2015.07.041]

21 Faisa S, Pereira L, Luis A, Chaves P, Cravo M. Genetic testing for microfoccessi biopsy of pancreatic cysts: Systematic review and meta-analysis. *World J Gastroenterol* 2019; 25: 3450-3467 [PMID: 31341386 DOI: 10.3748/wjg.v25.i26.3450]

22 Yang D, Trinadade AJ, Yachimish B, Penias B, Nito J, Manvar A, Ho S, Esnakula A, Gambo A, Seth A, Gup A, Khara HS, Diehl DL, El Chafic A, Shah J, Forsmark CE, Draganov PV, Paulino J, von Hooff J, Karchin R, Naito Y, Gupta K, Hogg M, Lee KK, Tsung A, Zureikah AI, Wald AI, Nikiforova MN. Preoperative next-generation sequencing of pancreatic cystic fluid is highly accurate in cyst classification and detection of advanced neoplasia. *Gastroenterology* 2019; 157: 1587-1596 [PMID: 30471456 DOI: 10.1016/j.cgh.2018.11.027]

23 Tacelli M, Celsa C, Magro B, Barchiesi M, Baroisi L, Capurso G, Arcidiacono PG, Cammà C, Crinò SF. Diagnostic performance of endoscopic ultrasound through-the-needle microfoccessi biopsy of pancreatic cystic lesions: Systematic review with meta-analysis. *Dig Endosc* 2020 [PMID: 31912580 DOI: 10.1111/den.13626]

24 Facciorussa A, Del Prete V, Antonino M, Buccino VR, Wani S. Diagnostic yield of EUS-guided through-the-needle biopsy in pancreatic cysts: a meta-analysis. *Gastrointest Endosc* 2020; 92: 1510-1520 [PMID: 32014422 DOI: 10.1016/j.gie.2020.01.038]

25 Larghi A, Manfri F, Fabbi C, Crinò SF, Correale L, Chiarello G, Barroisi L, Van Velthuyzen ML, Polew JW, Rahal D, Carrara S, Inzani F, Formelli A, Inzani F, Eron SDS, et al. Intraductal papillary mucinous neoplasm: an endoscopic ultrasound-guided through-the-needle microfoccessi biopsy samples for evaluation of pancreatic cystic lesions. *Gastrointest Endosc* 2019; 90: 784-792.e4 [PMID: 31323322 DOI: 10.1016/j.gie.2019.07.011]

26 Barroisi L, Calvani G, Barroisi L, Traina M, Stratifing Intraductal Papillary Mucinous Neoplasms by EUS-Guided Through-the-Needle Microfoccessi Biopsy Specimens. *Am J Gastroenterol* 2018; 113: 1059-1060 [PMID: 29899433 DOI: 10.1038/s41395-018-0124-6]

27 Barroisi L, Calvani G, Barroisi L, Traina M, Stratifing Intraductal Papillary Mucinous Neoplasms by EUS-Guided Through-the-Needle Microfoccessi Biopsy Specimens. *Am J Gastroenterol* 2018; 88: 771-774 [PMID: 29980179 DOI: 10.1038/s41395-018-0008.006]
evaluation of pancreatic cystic lesions (with video). Gastrointest Endosc 2015; 87: 1263-1269 [PMID: 26428198 DOI: 10.1007/s00464-015-4510-5]

Napoléon B, Lemaistre AI, Pujol B, Caillié F, Lucidarme D, Bourdariat R, Moreillon-Malbée B, Furnex F, Lefort C, Lepilépie Y, Palazzo L, Monges G, Poizat F, Giovanni M. In vivo characterization of pancreatic cystic lesions by needle-based confocal laser endomicroscopy (nCLE): proposition of a comprehensive nCLE classification confirmed by an external retrospective evaluation. Surg Endosc 2016; 30: 2603-2612 [PMID: 26428198 DOI: 10.1007/s00464-015-4510-5]

Napoléon B, Palazzo M, Lemaistre AI, Caillié F, Palazzo L, Aubert A, Busclau L, Maire F, Moreillon BM, Pujol B, Giovanni M. Needle-based confocal laser endomicroscopy of pancreatic cystic lesions: a prospective multicenter validation study in patients with definite diagnosis. Endoscopy 2019; 51: 825-835 [PMID: 30347425 DOI: 10.1055/a-0732-5336]

Krishna SG, Hart PA, Malii A, Kruger AJ, McCarthy ST, El-Dika S, Dillhoff ME, Manilchuk A, Schmidt CR, Pawlik TM, Porter K, Arnold CA, Cruz-Monserrate Z, Conwell DL. Endoscopic Ultrasound-Guided Confocal Laser Endomicroscopy Increases Accuracy of Differentiation of Pancreatic Cystic Lesions. Clin Gastroenterol Hepatol 2020; 18: 432-440.e6 [PMID: 31220640 DOI: 10.1016/j.cgh.2019.06.010]

Krishna SG, Modi RM, Kamboj AK, Swanson BJ, Hart PA, Dillhoff ME, Manilchuk A, Schmidt CR, Conwell DL. In vivo and ex vivo confocal endomicroscopy of pancreatic cystic lesions: A prospective study. World J Gastroenterol 2017; 23: 3338-3348 [PMID: 28566699 DOI: 10.3748/wjg.v23.i18.3338]

Krishna SG, Swanson B, Conwell DL, Muscarella P. 2nd. In vivo and ex vivo needle-based confocal endomicroscopy of intraductal papillary mucinous neoplasm of the pancreas. Gastrointest Endosc 2015; 82: 571-572 [PMID: 26005013 DOI: 10.1016/j.gie.2015.04.021]

Krishna SG, Brugge WR, Dewitt JM, Kongkam P, Napoléon B, Robles-Medranda C, Tan D, El-Dika S, McCarthy S, Walker J, Dillhoff ME, Manilchuk A, Schmidt C, Swanson B, Shah ZK, Hart PA, Conwell DL. Needle-based confocal laser endomicroscopy for the diagnosis of pancreatic cystic lesions: an international external interobserver and intraobserver study (with videos). Gastrointest Endosc 2017; 86: 644-654.e2 [PMID: 28286093 DOI: 10.1016/j.gie.2017.06.002]

Basturs O, Hong SM, Wood LD, Asad NY, Albores-Saavedra J, Blakkin AV, Brosens LA, Fukushima N, Goggins M, Hruban RH, Kato Y, Kimstra DS, Klöppel G, Krasinskas A, Longnecker DS, Matthei H, Offerhaus GJ, Shimizu M, Takaori K, Terris B, Yachida S, Esposito I, Furuwaka T; Baltimore Consensus Meeting. A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas. Am J Surg Pathol 2015; 39: 1730-1741 [PMID: 26593777 DOI: 10.1097/PAS.0000000000000533]

Cooper CL, O'Toole SA, Kench JG. Classification, morphology and molecular pathology of premalignant lesions of the pancreas. Pathology 2013; 45: 286-304 [PMID: 23442735 DOI: 10.1097/PAT.0b013e32833f1440]

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69: 7-34 [PMID: 30626902 DOI: 10.3322/cac.21551]

Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, Falconi M, Shimizu M, Yamaguchi K, Yamao K, Matsuo S, International Association of Pancreatologists. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006; 6: 17-32 [PMID: 16327281 DOI: 10.1159/000090023]

Tanaka M, Fernandez-del Castillo C, Adsay V, Chari S, Falconi M, Jang JY, Kimura W, Levy P, Pitman MB, Schmidt CM, Shimizu M, Wolfgang CL, Yamaguchi K, Yamao K; International Association of Pancreatologists. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012; 12: 183-197 [PMID: 22683731 DOI: 10.1016/j.pan.2012.04.006]

Ganjoue S, Brennan MF, Gonen M, D'Angelica M, DeMatteo RP, Jr., Janakos M, Jarnagin WR, Allen PJ. Cystic lesions of the pancreas: changes in the presentation and long-term survival of resected pancreatic cystic neoplasms in Finland. The first nationwide retrospective cohort analysis. Pancreatology 2019; 19: 456-461 [PMID: 30808537 DOI: 10.1016/j.pan.2019.02.007]

Jones M, Zheng Z, Wang J, Dudley J, Albanese E, Kadavilifci A, Dias-Santagata D, Le L, Brugge WR, Fernandez-del Castillo C, Minno-Kenudson M, Iafriate AJ, Pitman MB. Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts. Gastroenterology 2016; 83: 140-148 [PMID: 26235016 DOI: 10.1053/j.gastro.2015.06.047]

Rosenbaum MW, Jones M, Dudley JC, Le LP, Iafriate AJ, Pitman MB. Next-generation sequencing adds value to the preoperative diagnostic evaluation of pancreatic cysts. Cancer Cytopathol 2017; 125: 41-47 [PMID: 27847802 DOI: 10.1002/1097-222X.cct.20175]

Basar O, Yıkoel O, Yang DJ, Samarasekara J, Forecione D, DiMaio CJ, Wahg MS, Chang K, Casey B, Fernandez-Del Castillo C, Pitman MB, Brugge WR. Feasibility and safety of microforceps biopsy in the diagnosis of pancreatic cysts. Gastrointest Endosc 2018; 88: 79-86 [PMID: 29510146 DOI: 10.1016/j.gie.2018.02.039]

Mittal C, Obach JC, Hammad H, Edmundowicz SA, Wani S, Shah RJ, Brauer BC, Attwell AR, Kaplan JB, Wahg MS. Technical feasibility, diagnostic yield, and safety of microforceps biopsies during EUS evaluation of pancreatic cystic lesions (with video). Gastroenterology 2018; 87: 1263-1269 [PMID: 29510146 DOI: 10.1016/j.gie.2018.02.039]
Yang D, Samarasena JB, Jamil LH, Chang KJ, Lee D, Ona MA, Lo SK, Gaddam S, Liu Q, Draganov PV. Endoscopic ultrasound-guided through-the-needle microforceps biopsy in the evaluation of pancreatic cystic lesions: a multicenter study. *Endosc Int Open* 2018; 6: E1423-E1430 [PMID: 30574535 DOI: 10.1055/a-0770-2700]

Zhang ML, Arpin RN, Brugge WR, Forcione DG, Basar O, Pitman MB. Moray micro forceps biopsy improves the diagnosis of specific pancreatic cysts. *Cancer Cytopathol* 2018; 126: 414-420 [PMID: 29660844 DOI: 10.1002/cncy.21988]

Crinò SF, Bernardoni L, Brozzi L, Barresi L, Malleo G, Salvia R, Frulloni L, Sina S, Parisi A, Remo A, Larghi A, Gabbielli A, Manfrin E. Association between macroscopically visible tissue samples and diagnostic accuracy of EUS-guided through-the-needle microforceps biopsy sampling of pancreatic cystic lesions. *Gastrointest Endosc* 2019; 90: 933-943 [PMID: 31100310 DOI: 10.1016/j.gie.2019.05.009]
